Researchers evaluated 7,637 type 2 diabetes patients, mean age of 65, and found that 8.5% of those on degludec experienced a major cardiovascular event and 4.9% had prespecified adjudicated severe hypoglycemia, compared with 9.3% and 6.6% of those on glargine, respectively. The findings, published in The New England Journal of Medicine and presented at the American Diabetes Association's meeting, also revealed a significantly lower fasting plasma glucose level among those who received degludec than those in the glargine group.
Study compares health outcomes with degludec, glargine in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.